Natera

Natera Debt

The Debt of Natera (NTRA) as of Nov 22, 2026 is 214.38 M USD. In the previous year, Debt was 187.12 M USD — a change of 14.57% (higher).

Debt

214.38 MUSD

YoY

14.57%

Last updated:

In 2025, Natera's total debt was 214.38 M USD, a 14.57% change from the 187.12 M USD total debt recorded in the previous year.

The Natera Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
123.51 M USD
Jan 1, 2019
155.82 M USD
Jan 1, 2020
281.09 M USD
Jan 1, 2021
397.23 M USD
Jan 1, 2022
446.22 M USD
Jan 1, 2023
441.99 M USD
Jan 1, 2024
187.12 M USD
Jan 1, 2025
214.38 M USD
The Natera Debt history
YEARDebtYoY
214.38 MUSD+14.57%
187.12 MUSD-57.66%
441.99 MUSD-0.95%
446.22 MUSD+12.33%
397.23 MUSD+41.32%
281.09 MUSD+80.40%
155.82 MUSD+26.16%
123.51 MUSD+0.27%
123.18 MUSD+148.22%
49.62 MUSD+17.90%
42.09 MUSD+56.97%
26.81 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Natera Stock analysis

What does Natera do? Natera Inc. is an American company headquartered in San Carlos, California. It was founded in 2004 by Matthew Rabinowitz and has been listed on the NASDAQ under the ticker symbol "NTRA" since 2015. The company is a leading provider of diagnostic tests and analyses and specializes in genetic analysis and diagnostic technologies. Natera specializes in tests for various medical areas, particularly in oncology diagnostics. The company's vision is to improve the quality of life for millions of people worldwide by offering innovative diagnostic tests to detect diseases early and ensure optimal treatment. Natera offers a wide range of products tailored to the needs of consumers, physicians, and scientists. The company operates in three business areas: 1) Women's Health: Natera offers tests for women and couples to determine the risk of hereditary diseases. For example, the company offers a test that allows analysis of fetal DNA from the mother's blood, allowing detection of genetic abnormalities in the fetus before birth. Additionally, Natera offers the Panorama test, which provides tests for genetic anomalies in unborn babies that can be used to determine the risk for chromosomal abnormalities and genetic mutations. 2) Oncology: In the field of oncology, Natera offers a wide range of diagnostic tests targeting developments and trends in cancer research. The tests aim to enable accurate diagnosis and prognosis, as well as provide individualized treatment for each patient. The company offers tests that assess the current tumor growth and metastatic potential, enable determination of tumor burden in cells, and provide tests for specific mutations required for determining optimal treatment. 3) Genomic Analysis: In the field of genomic analysis, Natera offers a broad range of tests available to researchers and scientists. This includes genetic variants and biological mechanisms that cause diseases. The company is also committed to developing its tests through artificial intelligence (AI) and machine learning. The goal is to provide more accurate and faster results, improve clinical decisions, and advance research and development of new diagnostics. Conclusion: Natera is a leading company in the field of diagnostic tests and analyses in the field of genomic analysis. The company has a long history of research and development of innovative product solutions for the medical community. One important focus of the company is to improve women's health and be able to detect risks for genetic diseases early; the other focus is on oncology diagnostic tools to determine optimal treatment for cancer patients. The company is constantly striving to further develop its tests and integrate new research findings and technologies to support the medical science community. Natera is one of the most popular companies on Eulerpool.

Debt Details

Understanding Natera's Debt Structure

Natera's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Natera's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Natera’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Natera’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Natera stock

Debt of Natera is 214.38 M USD in 2025.

Debt of Natera changed from 187.12 M USD to 214.38 M USD, representing a 14.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Natera since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Natera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Natera

All Key Metrics — Natera